{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:28:41Z","timestamp":1768318121983,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ijmmb.2024.100565","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T11:33:51Z","timestamp":1711452831000},"page":"100565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Antimicrobial efficacy of eravacycline against emerging extensively drug-resistant (XDR) Acinetobacter baumannii isolates"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9666-5434","authenticated-orcid":false,"given":"Hitender","family":"Gautam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid","family":"Raza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9455-6780","authenticated-orcid":false,"given":"Jaya","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarita","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benu","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arti","family":"Kapil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bimal K.","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ijmmb.2024.100565_bib1","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1164\/rccm.201102-0349OC","article-title":"Asian network for surveillance of resistant pathogens study group. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia","volume":"184","author":"Chung","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ijmmb.2024.100565_bib2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4161\/viru.19700","article-title":"Acinetobacter baumannii: an emerging opportunistic pathogen","volume":"3","author":"Howard","year":"2012","journal-title":"Virulence"},{"issue":"5","key":"10.1016\/j.ijmmb.2024.100565_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jcrc.2010.12.016","article-title":"A multidrug-resistant Acinetobacter baumannii outbreak in intensive care unit: antimicrobial and organizational strategies","volume":"26","author":"Consales","year":"2011","journal-title":"J Crit Care"},{"key":"10.1016\/j.ijmmb.2024.100565_bib4","article-title":"Gram-negative infections in adult intensive care units of Latin america and the Caribbean","volume":"2014","author":"Luna","year":"2014","journal-title":"Crit Care Res Pract"},{"issue":"1","key":"10.1016\/j.ijmmb.2024.100565_bib5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of acinetobacter infections: a century of challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijmmb.2024.100565_bib6","first-page":"778","volume":"vol. 9","author":"Talebi Bezmin Abadi","year":"2019"},{"key":"10.1016\/j.ijmmb.2024.100565_bib7","unstructured":"Biggest Threats and Data. Antibiotic. Antimicrobial Resistance. CDC. Available online: https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html#acine (accessed on 16 April 2022).."},{"issue":"3","key":"10.1016\/j.ijmmb.2024.100565_bib8","first-page":"420","article-title":"The United States food and drug administration and the end of antibiotics","volume":"34","author":"Shlaes","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ijmmb.2024.100565_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jhm.2477","article-title":"Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study","volume":"11","author":"Zilberberg","year":"2016","journal-title":"J Hosp Med"},{"issue":"3","key":"10.1016\/j.ijmmb.2024.100565_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.ijmmb.2024.100565_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.48.9.3298-3304.2004","article-title":"Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system","volume":"48","author":"Marchand","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.ijmmb.2024.100565_bib12","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/AAC.02556-12","article-title":"RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: major role for AdeABC overexpression and AdeRS mutations","volume":"57","author":"Yoon","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ijmmb.2024.100565_bib13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1473-3099(08)70279-2","article-title":"Current control and treatment of multidrug-resistant Acinetobacter baumannii infections","volume":"8","author":"Karageorgopoulos","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.ijmmb.2024.100565_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing enterobacteriaceae","volume":"31","author":"Rodr\u00edguez-Ba\u00f1o","year":"2018","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 5","key":"10.1016\/j.ijmmb.2024.100565_bib15","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"10.1016\/j.ijmmb.2024.100565_bib16","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijmmb.2024.100565_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijantimicag.2012.09.005","article-title":"The emergence of clinical resistance to tigecycline","volume":"41","author":"Sun","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"10.1016\/j.ijmmb.2024.100565_bib18","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cid\/civ048","article-title":"Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance","volume":"60","author":"Qureshi","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ijmmb.2024.100565_bib19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijantimicag.2016.07.007","article-title":"Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients","volume":"48","author":"Tsioutis","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.ijmmb.2024.100565_bib20","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijmmb.2024.100565_bib21","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.06187-11","article-title":"Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic","volume":"56","author":"Grossman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2024.100565_bib22","series-title":"Performance Standards For Antimicrobial Susceptibility Testing","year":"2020"},{"key":"10.1016\/j.ijmmb.2024.100565_bib23","series-title":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters","year":"2021"},{"issue":"19","key":"10.1016\/j.ijmmb.2024.100565_bib24","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMra0904124","article-title":"Hospital-acquired infections due to gram-negative bacteria","volume":"362","author":"Peleg","year":"2010","journal-title":"N Engl J Med"},{"issue":"6 Suppl1","key":"10.1016\/j.ijmmb.2024.100565_bib25","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.amjmed.2006.03.012","article-title":"Antimicrobial resistance in gram-positive bacteria","volume":"119","author":"Rice","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.ijmmb.2024.100565_bib26","article-title":"Pharmacokinetics, safety and tolerability of a novel fluorocycline, TP-434, following multiple-dose oral administration with and without food","volume":"20","author":"Horn","year":"2011","journal-title":"In 49th Infectious Diseases Society of America Annual Meeting"},{"key":"10.1016\/j.ijmmb.2024.100565_bib27","article-title":"Population pharmacokinetic modelling of TP-434, a novel fluorocycline, following single and multiple dose administration","author":"Seng Yue","year":"2010","journal-title":"abstr A1-028. In Abstr 50th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"10.1016\/j.ijmmb.2024.100565_bib28","series-title":"Eur. Congr. Clin. Microbiol. Infect. Dis.\/27th int. Congr. Chemother., Milan, Italy","article-title":"Broad-spectrum fluorocycline TP-434 has oral bioavailability in humans","author":"Leighton","year":"2011"},{"issue":"11","key":"10.1016\/j.ijmmb.2024.100565_bib29","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2024.100565_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-61779-588-6_6","article-title":"A practical introduction to molecular dynamics simulations: applications to homology modeling","volume":"857","author":"Nurisso","year":"2012","journal-title":"Methods Mol Biol"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085724000409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085724000409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T20:22:00Z","timestamp":1714854120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085724000409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":30,"alternative-id":["S0255085724000409"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmmb.2024.100565","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial efficacy of eravacycline against emerging extensively drug-resistant (XDR) Acinetobacter baumannii isolates","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmmb.2024.100565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100565"}}